Cerebrotendinous Xanthomatosis, a Treatable Disorder Often Missed: Case Series of Three Patients Confirmed by Genetic Testing
Authors:
Open Access
- 1 January 2024
- journal article
- research article
- Published by Medknow in Neurology India
- Vol. 72 (1) , 138-141
Abstract
Cerebrotendinous xanthomatosis (CTX) is a treatable autosomal recessive disorder with varied clinical manifestations and age of onset and is often diagnosed late. We report three cases of CTX who presented at our center with clinical features of frequent diarrhea, early cataracts, xanthomas, cognitive decline, ataxia, neuropathy, and other manifestations of CTX. Magnetic resonance imaging (MRI) brain in all three patients revealed abnormalities consistent with CTX. Diagnosis was confirmed by next-generation sequencing. Chenodeoxycholic acid (CDCA) is recommended as the drug of choice, as it can halt the disease progression and reverse some of the symptoms. In addition to late diagnosis, nonavailability of CDCA in our part of world adds to the problem of management of such patients; therefore, they are often started on alternative therapies, which are less effective.Keywords
This publication has 16 references indexed in Scilit:
- Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosisJournal of Clinical Lipidology, 2018
- Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX)Journal of Inherited Metabolic Disease, 2017
- Clinical and molecular diagnosis of cerebrotendinous xanthomatosis with a review of the mutations in the CYP27A1 geneNeurological Sciences, 2006
- Cerebrotendinous XanthomatosisArchives of Neurology, 2005
- Transcriptional activation of the cholesterol 7α-hydroxylase gene (CYP7A) by nuclear hormone receptorsJournal of Lipid Research, 1998
- Ocular and Systemic Manifestations of Cerebrotendinous XanthomatosisAmerican Journal of Ophthalmology, 1995
- Osteoporosis and increased bone fractures in cerebrotendinous xanthomatosisMetabolism, 1993
- Chenodeoxycholic acid normalizes elevated lipoprotein secretion and catabolism in cerebrotendinous xanthomatosis.Journal of Lipid Research, 1989
- Bile acid therapies applied to patients suffering from cerebrotendinous xanthomatosisClinica Chimica Acta, 1985
- Chenodeoxycholic acid inhibits increased cholesterol and cholestanol synthesis in patients with cerebrotendinous XanthomatosisBiochemical Medicine, 1975